Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will hold
its Annual Meeting of Stockholders on Thursday, May 21, 2009 beginning
at 10:00 am Eastern Time at the Crowne Plaza Hotel, 3 Research Court,
Rockville, MD, 20850.
At the annual meeting, stockholders will consider and vote on the
following matters:
-
the election of Daniel J. Abdun-Nabi and Dr. Sue Bailey to serve as
Class III directors, each for a term of three years;
-
the approval of the company’s Amended and Restated 2006 Stock
Incentive Plan, which is proposed primarily for, among other purposes,
increasing the number of shares authorized for issuance under our 2006
Stock Incentive Plan by 3,900,000 shares and extending the term of the
plan from December 31, 2009 to December 31, 2019; and
-
the ratification of the selection by the audit committee of Ernst &
Young LLP as the company’s independent registered public accounting
firm for the fiscal year ending December 31, 2009.
Stockholders also will consider and vote on any other matters as may
properly come before the annual meeting or any adjournment or
postponement thereof. The company’s board of directors has no knowledge
of any other matters which may come before the meeting.
Stockholders of record at the close of business on March 27, 2009 are
entitled to notice of, and to vote at, the annual meeting or any
adjournment or postponement thereof.
If you plan to attend the meeting, please bring photo identification for
admission. Also, if your shares are held in the name of a broker, bank
or other nominee, please bring with you a proxy, letter or account
statement (or copy thereof) from your broker, bank or nominee confirming
your ownership of Emergent BioSolutions stock so that you can be
admitted to the meeting. Also, if your shares are held of record by a
broker, bank or other nominee and you wish to vote at the meeting, you
must obtain a broker’s proxy card issued in your name.
Interested parties may listen to the Annual Meeting via conference call
by dialing either 866/314-5232 in the U.S. or 617/213-8052 outside the
U.S. No passcode is required for the live call. Interested parties may
also access a webcast of the Annual Meeting by visiting the Emergent
BioSolutions website at www.emergentbiosolutions.com.
A replay of the teleconference will be available approximately one hour
following the conclusion of the call by dialing 888/286-8010 or
617/801-6888 and using the passcode 73054208. The replay will be
available through July 28. In addition, the webcast will be archived on
the company’s website, www.emergentbiosolutions.com,
under "Investors”.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and
therapeutics that assist the body’s immune system to prevent or treat
disease. Emergent’s marketed product, BioThrax® (Anthrax
Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and
Drug Administration for the prevention of anthrax. Emergent’s
development pipeline includes programs focused on anthrax, botulism,
tuberculosis, typhoid, hepatitis B and chlamydia. Additional information
may be found at www.emergentbiosolutions.com.
Safe Harbor Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and
objectives of management, including any potential future securities
offering, and any other statements containing the words "believes”,
"expects”, "anticipates”, "plans”, "estimates” and similar expressions,
are forward-looking statements. There are a number of important factors
that could cause the company's actual results to differ materially from
those indicated by such forward-looking statements, including the timing
of, and the potential for successful outcomes resulting from future
product development efforts and our ability to obtain additional funding
from the U.S. government, our plans to expand our manufacturing
facilities and capabilities; the rate and degree of market acceptance
and clinical utility of our products; and other factors identified in
the company's quarterly report on Form 10-Q for the period ended March
31, 2009 and subsequent reports filed with the SEC. The company
disclaims any intention or obligation to update any forward-looking
statements as a result of developments occurring after the date of this
press release.
